Prelude Therapeutics Stock (NASDAQ: PRLD)

Prelude Therapeutics

PRELUDE THERAPEUTICS INC

Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

Lululemon, Applovin Corp, Hertz, Rivian, Tesla: Why These 5 Stocks Are On Investors' Radars Today

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ALTG

ASTI

BRZE

DRCT

DRMA

KULR

LGMK

LULU

MERC

PAPL

PRLD

PRTG

PTIX

RNAZ

SNSE

STSS

XTIA

Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

Lattice Semiconductor

ACLS

AMKR

BHAT

BNAI

FLNC

GNPX

HLIT

LIXT

LSCC

NLSP

OCEA

SGRY

SLQT

SLXN

TANH

VSTE

Why Lattice Semiconductor Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

UBS sign

Intraday Update

ANAB

CLOV

FLUT

INTA

LPLA

MRCY

NKTX

PFGC

QFIN

SDHC

SERV

VSCO

UBS Posts Upbeat Earnings, Joins Victoria&#39;s Secret, Performance Food Group, Kellanova And Other Big Stocks Moving Higher On Wednesday

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics Inc

Earnings

Press Releases

Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Health Care

Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024

Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium

Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium

Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit

Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference

Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025

Agenus

Aligos Therapeutics

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

Celularity

CytomX Therapeutics

Dyadic International, Inc. - Common Stock

Dyadic International

Fortress Biotech

Forte Biosciences

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics

iBio

MiNK Therapeutics

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Lantern Pharma

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

OKYO Pharma

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

PepGen

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics

Rein Therapeutics

Skye Bioscience

Surrozen

Shattuck Labs

X4 Pharmaceuticals

Xilio Therapeutics

Citizens Capital Markets

JMP Securities

HC Wainwright & Co.

Morgan Stanley

Barclays

Comments

Prelude Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga